Press coverage about Merck & (NYSE:MRK) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Merck & earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.9944955883348 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Merck & (MRK) traded up $0.10 on Thursday, hitting $54.37. The stock had a trading volume of 7,374,403 shares, compared to its average volume of 9,591,982. The firm has a market cap of $147,855.20, a price-to-earnings ratio of 13.95, a P/E/G ratio of 2.34 and a beta of 0.78. Merck & has a 12 month low of $53.63 and a 12 month high of $66.80. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57.

Merck & (NYSE:MRK) last released its earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.08. The company had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. Merck &’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.07 EPS. equities analysts anticipate that Merck & will post 3.95 EPS for the current year.

A number of research analysts have commented on MRK shares. Cowen and Company reaffirmed a “hold” rating and issued a $70.00 price objective on shares of Merck & in a report on Friday, November 3rd. J P Morgan Chase & Co set a $70.00 price objective on Merck & and gave the company a “buy” rating in a report on Sunday, October 29th. Zacks Investment Research lowered Merck & from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “sell” rating and issued a $55.00 price objective on shares of Merck & in a report on Friday, October 20th. Finally, Barclays PLC lowered Merck & from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $72.00 to $62.00 in a report on Monday, October 30th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $66.87.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Merck & (MRK) Stock Price” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/11/23/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-merck-mrk-stock-price.html.

In other news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.25% of the company’s stock.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Insider Buying and Selling by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.